Four executives from the gas carrier operator joined seven from the midstream pipeline company ... A photo of the terminal, along with each company’s logo, was featured on their jerseys.

HOUSTON, May 06, 2025--(BUSINESS WIRE)--Hess Midstream LP (NYSE: HESM) ("Hess Midstream"), today announced an accretive $200 million repurchase that included both Class B units by its subsidiary ...

Hess Midstream (NYSE:HESM) has made an accretive $200M repurchase from both its sponsors and the public. The company entered into an accelerated share repurchase agreement with JPMorgan Chase Bank ...

THE WOODLANDS, Texas (AP) — THE WOODLANDS, Texas (AP) — Western Midstream Partners, LP (WES) on Wednesday reported first-quarter earnings of $309 million. The The Woodlands, Texas-based ...

Antero Midstream's (NYSE:AM) 2025 guidance was a bit better than I expected, with it expecting low-single digits throughput growth despite Antero Resources (AR) aiming for roughly flat year-over ...

Antero Midstream's estimated fair value is US$33.20 based on 2 Stage Free Cash Flow to Equity Antero Midstream's US$17.53 share price signals that it might be 47% undervalued The US$16.50 analyst ...

Hess Midstream (NYSE:HESM) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-30. Here's a quick overview of what investors should know before the release. Analysts are ...

Looking at the universe of stocks we cover at Dividend Channel, on 5/8/25, Hess Midstream LP (Symbol: HESM) will trade ex-dividend, for its quarterly dividend of $0.7098, payable on 5/14/25.

You can find higher-yielding midstream players than Enterprise Products Partners. It is hard to find midstream stocks that are more reliable than Enterprise. Like most midstream players ...

DT Midstream DTM will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement. Analysts anticipate DT Midstream to report an ...

Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company. The antibody-drug-conjugate-focused biotech has come under fire from ...